Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approves subcutaneous administration of Entyvio (vedolizumab) for maintenance therapy in moderately to severely active Crohn’s disease – Takeda

Written by | 29 Apr 2024

Takeda announced that the FDA has approved Entyvio (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy… read more.

Skyrizi met all primary and secondary endpoints versus Stelara in head-to-head study in Crohn’s disease – AbbVie

Written by | 16 Sep 2023

AbbVie announced top-line results from the Phase III SEQUENCE clinical trial evaluating risankizumab (Skyrizi, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg… read more.

EU approves Rinvoq in Crohn’s disease – AbbVie

Written by | 1 Jun 2023

AbbVie announced the European Commission (EC) approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK)… read more.

Interim data from INSPIRE study of Alofisel shows clinical remission rate in Crohn’s disease – Takeda

Written by | 2 Apr 2022

Takeda announced the first six-month interim analysis results from INSPIRE, in which clinical remission was observed in 65% of patients in both cohorts who were evaluated at 6… read more.

Janssen presents results of first head-to-head study of biologic therapies in patients with moderate to severe Crohn’s disease

Written by | 12 Jun 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced efficacy and safety data for Stelara (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),including data from the SEAVUE… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.